Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc., reported multiple sales of common stock totaling 95,179 shares in early December 2025.

Summary

• Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), reported the sale of 95,179 shares of common stock across three separate transactions in December 2025.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• On December 5, 2025, 16,568 shares were sold at a weighted average price of $0.97 per share, with prices ranging from $0.9434 to $0.9863.
• On December 8, 2025, an additional 34,041 shares were sold at a weighted average price of $0.99 per share, with prices ranging from $0.9582 to $1.01.
• On December 9, 2025, 44,570 shares were sold at a weighted average price of $1.01 per share, with prices ranging from $0.99 to $1.025.
• Following these transactions, the indirect beneficial ownership by entities associated with Luke Evnin stands at 2,973,099 shares of common stock.

Sentiment

Score: 4

Explanation: The sale of shares by a director and 10% owner, even under a pre-arranged plan, typically carries a slightly negative sentiment as it can be perceived as a lack of confidence in the company's future stock performance. The relatively low share price at which sales occurred (around $1.00) might also be a concern.

Negatives

• The sale of a significant number of shares by a Director and 10% owner, even under a pre-arranged plan, can be perceived negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects or valuation.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide specific insights into broader industry trends for biotechnology or oncology. It reflects individual investment decisions by a director and 10% owner rather than strategic company or industry-wide developments.

Related Party Transactions

• Luke Evnin, a Director and 10% owner, reported sales of common stock through entities where he holds significant influence, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.
• Evnin disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, indicating an indirect beneficial ownership structure.

Stakeholder Impact

• Shareholders may interpret the insider sales as a signal regarding management's confidence in the company's future prospects, potentially leading to negative sentiment or downward pressure on the stock price.
• The transactions do not directly impact employees, customers, suppliers, or creditors, as they relate solely to equity ownership changes by an insider.

Key Dates

Recommendation

While insider sales by a director and 10% owner can be a negative signal, these transactions were executed under a pre-established 10b5-1 plan, which mitigates some of the immediate negative implications. The sales occurred at prices around $1.00, which is relatively low. Without additional context on the company's fundamentals, financial performance, or strategic outlook, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for a more comprehensive view, as these sales alone do not provide a complete picture for a 'buy' or 'sell' decision.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Biotechnology, Equity Transaction